GlobeNewswire

New Axonify Study Reveals Microlearning Key to Enabling an Agile Frontline Workforce

Dela

First-of-its-Kind 2018 Microlearning Global Benchmark Report Highlights Progressive Organisations Reimagining Training

WATERLOO, Ontario, July 25, 2018 (GLOBE NEWSWIRE) -- Highlighting the influence microlearning has in enabling an agile workforce, Axonify, the most trusted corporate microlearning platform, today launched the first-of-its-kind 2018 Microlearning Global Benchmark Report. The comprehensive analysis of microlearning covers general trends, adoption, demographics and industry applications based on usage data from 360,000 employees at 78 organisations using Axonify.

The report reveals how continuous microlearning takes learning measurement beyond traditional metrics like test scores and completion rates by providing stakeholders across the business with a real-time view of what employees know or don't know so that they can proactively respond to address gaps. According to the report, microlearning offers universal appeal among frontline-driven organisations and drives high levels of employee engagement directly impacting business results. Data shows that on average, employees utilising microlearning know 85 percent of the information they are required to know to perform on-the-job compared to 73% when they started.

Also, the report highlighted that three quarters of employees participate in microlearning training sessions at a rate of two to three times weekly, and it is heavily used in fast-paced, agile industries with a large number of frontline employees, including Retail (27 percent), Manufacturing and Logistics (25 percent) and Finance and Insurance (22 percent).

"Microlearning resonates with frontline workers because it's a habit-forming style of learning that fits seamlessly into their agile work environment-the first thing they do at the start of a shift or when they have downtime," said Carol Leaman, CEO of Axonify. "Traditionally, getting employees to participate in training has been tough, but that isn't the case with microlearning. It automatically adapts learning so each session is based on what an employee knows or doesn't know including game mechanics for increased engagement."

Anatomy of a Microlearning Session

Employees participating in microlearning training every month, do so two to three times per week which translates into more than 100 training sessions per year. Averaging six minutes per day, microlearning sessions typically start with critical messages from senior management, followed by personalised training, casual game play and rewards. Employees exposed to microlearning incorporating game play and game mechanics participate at a rate of 52 percent more, experiencing average knowledge lift of 27 percent.

"Microlearning is now becoming mainstream," said Josh Bersin, Global Industry Analyst. "This important research proves the value of this new paradigm and gives us all a clear roadmap for success."

Based on Axonify's research, organisations most often use microlearning to train their employees on:

  1. Product Knowledge
  2. Safety
  3. Sales
  4. HR/Corporate Culture
  5. Customer Service

"Fosway's research shows that almost two-thirds of organisations are planning to adopt microlearning this year, so it is clearly a growth area. But as with all buzzwords, there is a lot of hype and not enough context around the use and advantages of microlearning," said David Perring, Director of Research, Fosway Group. "This new report sheds light on some of its real-world application across a broad range of industries."

Retailers Take Advantage of Microlearning to Train Employees About Promotions

Retail, the largest cluster of organisations in Axonify's study includes frontline store associates across a variety of sectors including brand retailers, big box, grocery, and specialty retail. Across the industries covered in Axonify's report, retail employees have the highest Current Knowledge and Confidence at 84 percent, and their participation rate is high at 85 percent.

Aside from utilizing microlearning to advance product knowledge and safety measures, retailers are providing microlearning to train employees on promotions at a rate more than two times the industry average. Retailers are also embracing daily microlearning reinforcement as a critical preventative measure to keep shrink rates at bay using asset protection and loss prevention training.

Manufacturing and Logistics Mitigate Safety Risks with Microlearning

Manufacturers are increasingly turning to microlearning as a better way to mitigate high safety risks. In fact, safety training in Manufacturing and Logistics occurs at a rate of three times more than Finance and Insurance and almost two times more than retail. Safety training is the second most popular type of training offered, next to product knowledge, by manufacturing organisations as they work to achieve a company culture of safety.

Additionally, according to the study, microlearning helped lift manufacturing and logistics employees' product knowledge up to 91.4 percent. Also, based on their microlearning sessions, these professionals average a Current Knowledge and Confidence level of 83 percent with a 72 percent participation rate.

Methodology

The insights presented in the 2018 Microlearning Global Benchmark Report were generated by anonymously analysing a sample of 360,000 employees across 78 organisations, and nearly four million microlearning sessions that occurred between January 1, 2017 and December 31, 2017. This included a variety of industries and organisations ranging from mid-sized to large Fortune 100 companies-that are capturing millions of learning data points as employees engage in their daily training using the Axonify Microlearning Platform. 

For more information, visit https://axonify.com/benchmark-report/.

About Axonify

Axonify is the only microlearning platform trusted by global business leaders to drive performance. With a proven approach that's based in brain science, and uses adaptive microlearning and gamification to make employee learning effective and engaging, our platform ingrains knowledge deep enough to change employee behaviour at work. With more than 130 customers in 95 countries around the world, including Walmart, Bloomingdale's, and John Hancock, Axonify makes learning personal to the individual, and impactful for the business. Founded in 2011, Axonify is headquartered in Waterloo, ON Canada. For more information, please visit www.axonify.com.

Media Contact: 
Jennifer Mirabile
Young & Associates
724-772-2038
jenniferlm@yapr.com 




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Axonify via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Karolinska Development's portfolio company Aprea Therapeutics has received FDA Orphan Drug Designation and Fast Track Designation for APR-24616.4.2019 12:46:00 CESTPressmeddelande

STOCKHOLM, April 16, 2019. Karolinska Development's portfolio company Aprea Therapeutics has from FDA received an Orphan Drug Designation for APR-246 for the treatment of patients with Myelodysplastic Syndromes (MDS) having a TP53 mutation. In addition, FDA has also granted Fast Track Designation to APR-246 for treatment of MDS. Orphan Drug Designation is granted by the FDA Office of Orphan Products Development to advance the evaluation and development of safe and effective therapies for the treatment of rare diseases. The designation can provide development and commercial incentives for designated compounds and medicines, including eligibility for a seven-year period of market exclusivity in the U.S. after product approval, FDA assistance in clinical trial design, tax credits related to clinical trial expenses, and an exemption from FDA user fees. The FDA's Fast Track program facilitates the development of drugs intended to treat serious conditions and that have the potential to addre

Karolinska Developments portföljbolag Aprea Therapeutics har fått särläkemedelsstatus och snabbspårstatus från FDA för APR-24616.4.2019 12:46:00 CESTPressmeddelande

STOCKHOLM, SVERIGE - 16 april 2019. Karolinska Development AB meddelar idag att portföljbolaget Aprea Therapeutics har av FDA fått särläkemedelsstatus för APR-246 för behandling av patienter med TP53-muterad myelodysplastiskt syndrom (MDS). Dessutom ger FDA bolaget snabbspårstatus (Fast Track Designation), för APR-246 för behandling av MDS. Amerikanska läkemedelsverket, FDA, ger särläkemedelsstatus till läkemedelskandidater för att snabba på utvärderingen och utvecklingen av säkra och effektiva behandlingar av ovanliga sjukdomar. Särläkemedelsstatus ger företag både regulatoriska och kommersiella incitament genom att läkemedlet får marknadsexklusivitet på den amerikanska marknaden i sju år efter marknadsgodkännande samtidigt som företaget får stöd från FDA när det gäller designen av kliniska prövningar, skatteförmåner för kostnader kopplade till kliniska prövningar och avgiftsbefrielse från FDA. FDA:s snabbspår underlättar utvecklingen av läkemedel som är avsedda för att behandla allva

Bergman & Beving AB: Bergman & Beving förvärvar KGC10.4.2019 14:00:00 CESTPressmeddelande

Pressmeddelande Bergman & Beving förvärvar KGC Bergman & Beving har idag tecknat avtal om förvärv av samtliga aktier i KGC Verktyg & Maskiner AB. KGC, med säte i Älvsjö, har i mer än 60 år utvecklat och levererat kvalitetsverktyg och tillbehör för murning och plattsättning i det egna varumärket KGC. Bolaget omsätter cirka 80 MSEK per år, och har 24 anställda. "KGC är ett ledande varumärke med högt anseende hos murare och plattsättare och har en mycket stark ställning på den svenska marknaden", säger Pontus Boman, VD och koncernchef. Tillträde beräknas ske den 1 maj 2019 och förvärvet bedöms ha en marginellt positiv påverkan på Bergman & Bevings resultat per aktie under innevarande räkenskapsår. Stockholm den 10 april 2019 Bergman & Beving AB (publ) För ytterligare information kontakta: Pontus Boman, VD & Koncernchef, telefon 010-454 77 00 Peter Schön, CFO, telefon 070-339 89 99 Denna information lämnades, genom ovanstående kontaktpersoners försorg, för offentliggörande den 10 april 201

Bergman & Beving AB: Bergman & Beving acquires KGC10.4.2019 14:00:00 CESTPressmeddelande

Press release Bergman & Beving acquires KGC Bergman & Beving has today signed an agreement to acquire all shares in KGC Verktyg & Maskiner AB. KGC, based in Älvsjö, has for more than 60 years developed and delivered quality tools and accessories for bricklayers and tilers in its own brand KGC. The business has a turnover of approximately SEK 80 million per year, and has 24 employees. "KGC is a leading brand with high reputation among bricklayers and tilers and has a very strong position in the Swedish market," says Pontus Boman, President and CEO. The closing is taking effect on 1 May 2019 and the acquisition is expected to have a marginal positive impact on Bergman & Beving's earnings per share during the current fiscal year. Stockholm, 10 April 2019 Bergman & Beving AB (publ) For further information, please contact: Pontus Boman, President & CEO, Tel: +46 10 454 77 00 Peter Schön, CFO, Tel: +46 70 339 89 99 The information was submitted for publication, through the agency of the cont

Karolinska Development's portfolio company Aprea presents promising results with APR-246 in combination with immuno-oncology agents3.4.2019 14:00:00 CESTPressmeddelande

STOCKHOLM, April 3, 2019. Karolinska Development's portfolio company Aprea today presents results from studies with APR-246 in combination with immune checkpoint blockade. The results show that APR-246 can improve the effect of immuno-oncology agents. Karolinska Development portfolio company Aprea Therapeutics announced today the results of studies with APR-246 in combination with immune checkpoint blockade. The results were presented by researchers from Memorial Sloan Kettering Cancer Center at the 2019 AACR Annual Meeting in Atlanta. The studies collectively support a role for p53 activity in the tumor microenvironment and suggest that stabilization of the tumor suppressor protein, p53, by APR-246 can enhance anti-tumor immune response, particularly when combined with immuno-oncology agents. The studies characterized changes in the tumor immune microenvironment in melanoma and colorectal cancer in vivo models when treated with APR-246 and immuno-oncology agents, either alone or in co

Karolinska Development's portfolio company Aprea presents promising results with APR-246 in combination with immuno-oncology agents3.4.2019 14:00:00 CESTPressmeddelande

STOCKHOLM, April 3, 2019. Karolinska Development's portfolio company Aprea today presents results from studies with APR-246 in combination with immune checkpoint blockade. The results show that APR-246 can improve the effect of immuno-oncology agents. Karolinska Development portfolio company Aprea Therapeutics announced today the results of studies with APR-246 in combination with immune checkpoint blockade. The results were presented by researchers from Memorial Sloan Kettering Cancer Center at the 2019 AACR Annual Meeting in Atlanta. The studies collectively support a role for p53 activity in the tumor microenvironment and suggest that stabilization of the tumor suppressor protein, p53, by APR-246 can enhance anti-tumor immune response, particularly when combined with immuno-oncology agents. The studies characterized changes in the tumor immune microenvironment in melanoma and colorectal cancer in vivo models when treated with APR-246 and immuno-oncology agents, either alone or in co

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum